Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

Ipsen announces changes to its Executive Committee

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma

Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary...

Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

Ipsen publishes its 2024 Universal Registration Document

Ipsen announces issuance of €500 million inaugural Rated Public Bond